How to buy Exopharm (EX1) shares
Learn how to easily invest in Exopharm shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Exopharm is a biotechnology business based in Australia. Exopharm shares (EX1) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Exopharm has a trailing 12-month revenue of around $4.2 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Exopharm
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Exopharm . Find the share by name or ticker symbol: EX1. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Exopharm reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check on your investment. Congratulations, you own a part of Exopharm . Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
Exopharm stock price (ASX:EX1)Use our graph to track the performance of EX1 stocks over time.
Exopharm shares at a glance
|52-week range||$0.11 - $0.635|
|50-day moving average||$0.1839|
|200-day moving average||$0.3728|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.067|
Compare share trading platforms
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Exopharm stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Exopharm price performance over time
|1 week (2022-06-16)||10.34%|
|1 month (2022-05-26)||0.16|
|3 months (2022-03-25)||-47.54%|
|6 months (2021-12-24)||-66.32%|
|1 year (2021-06-25)||-69.23%|
|2 years (2020-06-26)||-34.69%|
|3 years (2019-06-26)||-61.90%|
|Revenue TTM||$4.2 million|
|Gross profit TTM||$61,104|
|Return on assets TTM||-48.57%|
|Return on equity TTM||-97.38%|
|Market capitalisation||$23.6 million|
TTM: trailing 12 months
Exopharm share dividends
We're not expecting Exopharm to pay a dividend over the next 12 months.
Exopharm share price volatility
Over the last 12 months, Exopharm 's shares have ranged in value from as little as $0.11 up to $0.635. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Exopharm 's is 1.2635. This would suggest that Exopharm 's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Exopharm Limited, a clinical-stage company, develops transformative medicines based upon extracellular vesicles (EVs) in Australia. The company's technology includes extracellular vesicle positioning system that allows specific molecules to be attached to the surface of exosomes to guide them to target tissues or cell types; leveraging oligonucleotide packing for amplified dosing, which enables specific RNA molecules to be preferentially loaded into exosomes as a therapeutic cargo; ligand-based exosome affinity purification that isolates and purifies exosomes from biofluids like blood and cell culture media. Its engineered EVs products comprise Fortrexo CoV for the treatment of SARS-CoV-2 infection; Cognevo for the treatment of neuro degeneration; and PlexoDox for the treatment of cancer. Exopharm Limited has a research collaboration with Showa Denko Materials Co., Ltd. The company was incorporated in 2013 and is based in Melbourne, Australia.
Stocks similar to Exopharm
Exopharm in the news
Frequently asked questions
More guides on Finder
How to buy Arcadia Minerals (AM7) shares
Steps to owning and managing Arcadia Minerals shares.
How to buy Nexgen Energy (NXG) shares
Steps to owning and managing Nexgen Energy shares.
How to buy Keypath Education (KED) shares
Steps to owning and managing Keypath Education shares.
What are green bonds and how do they impact the world?
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
5 best ways to invest money in Australia in 2022
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
How to buy EBR Systems (EBR) shares
Steps to owning and managing EBR Systems shares.
How to buy 5E Advanced Materials (5EA) shares
Steps to owning and managing 5E Advanced Materials shares.
How to buy Leo lithium shares
Steps to owning and managing Leo lithium shares.
How to buy Besra Gold (BEZ) shares
Steps to owning and managing Besra Gold shares.
How to buy The Lottery Corporation (TLC) shares
Steps to owning and managing The Lottery Corporation shares.
Ask an Expert